Charles Riv­er’s CD­MO busi­ness slows; Lil­ly boosts GLP-1 ca­pac­i­ty; Te­va’s Is­rael sites 'u­naf­fect­ed'

End­points News delved in­to an­oth­er week of in­vestor calls to gath­er key bio­phar­ma man­u­fac­tur­ing up­dates. We found that Charles Riv­er is look­ing to in­crease its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER